These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6157614)

  • 21. Factor-XIII subunits-A and -S in congenital deficiency and in acute myeloblastic leukemia.
    Barbui T; Rodeghiero F; Dini E
    Haematologica; 1974 Dec; 59(4):458-66. PubMed ID: 4219003
    [No Abstract]   [Full Text] [Related]  

  • 22. Defective fibrin crosslinking in acute leukemia.
    Rodeghiero F; Barbui T; Dal Belin-Peruffo A; Dini E
    Thromb Haemost; 1984 Dec; 52(3):343-6. PubMed ID: 6531757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA synthesis in leukemic cells under the action of cytotoxic agents in vitro and in vivo.
    Wilmanns W
    Natl Cancer Inst Monogr; 1971 Dec; 34():153-9. PubMed ID: 5291099
    [No Abstract]   [Full Text] [Related]  

  • 25. [Activity of fibrin stabilizing factor (FSF; factor XIII) in lymphoproliferative disorders].
    Kłoczko J; Zuch A; Bielawiec M; Buluk K
    Acta Haematol Pol; 1983; 14(1):13-9. PubMed ID: 6577768
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of anesthesia on blood coagulation factor XIII].
    Homann B; Blumenberg D; Lerner H
    Anaesthesist; 1984 Mar; 33(3):145-8. PubMed ID: 6721127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of the influence of age on remission rate and duration of remission in a group of thirty-four patients with acute myeloid leukaemia.
    De Vries EG; Mulder NH; Houwen B; Haaxma-Reiche H; De Vries-Hospers HG
    Neth J Med; 1980; 23(6):241-5. PubMed ID: 6936611
    [No Abstract]   [Full Text] [Related]  

  • 28. Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia.
    Nielsen HR; Killmann SA
    J Natl Cancer Inst; 1983 Nov; 71(5):887-91. PubMed ID: 6580488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)].
    Bauters F; Jouet JP; Huart JJ; Jude B; Toussaint B; Goudemand M
    Lille Med; 1980 Dec; 25(10):559-68. PubMed ID: 6936592
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor XIII-activity and fibrin subunit structure in acute leukemia.
    Rasche H; Dietrich M; Gaus W; Schleyer M
    Biomedicine; 1974 Feb; 21(2):61-6. PubMed ID: 4527804
    [No Abstract]   [Full Text] [Related]  

  • 33. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
    Langer F; Spath B; Haubold K; Holstein K; Marx G; Wierecky J; Brümmendorf TH; Dierlamm J; Bokemeyer C; Eifrig B
    Ann Hematol; 2008 Jun; 87(6):451-7. PubMed ID: 18292996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of the effect of cellular morphology on obtaining a complete remission in 99 cases of acute leukemia].
    Ríos A; Rozman C; Del Cañizo MC; Brugués R
    Sangre (Barc); 1984; 29(3):273-9. PubMed ID: 6592764
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cardiotoxic aspects of daunorubicin used in the treatment of acute myeloblastic and lymphoblastic leukoses].
    Topalov V; Popović K; Cikos J; Pejin D; Uzurov V
    Med Pregl; 1981; 34(3-4):119-22. PubMed ID: 6944597
    [No Abstract]   [Full Text] [Related]  

  • 36. Fibrinogen survival and fibrinopeptide A in acute leukemia.
    Castaman G; Galloni E; Dri AV; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):52-6. PubMed ID: 8039760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
    Sitar DS; Aoki FY; Bow EJ
    J Clin Pharmacol; 2008 Aug; 48(8):995-8. PubMed ID: 18495946
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of acute myeloblastic leukaemia.
    Br Med J; 1970 Nov; 4(5734):508-9. PubMed ID: 5274154
    [No Abstract]   [Full Text] [Related]  

  • 40. [Results of treatment with 2 chemotherapeutic protocols (TAPA and VAPA) in acute myeloblastic leukemia].
    Avilés-Miranda A; Ambriz-Fernández R; García-Vela E; Monroy-Arellano L; Pizzuto J
    Gac Med Mex; 1984 Apr; 120(4):145-50. PubMed ID: 6593266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.